| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9044402 | ZYLA | Abuse-deterrent pharmaceutical compositions for controlled release |
Jul, 2033
(9 years from now) | |
| US9549899 | ZYLA | Abuse deterrent pharmaceutical compositions for controlled release |
Jul, 2033
(9 years from now) | |
Arymo Er is owned by Zyla.
Arymo Er contains Morphine Sulfate.
Arymo Er has a total of 2 drug patents out of which 0 drug patents have expired.
Arymo Er was authorised for market use on 09 January, 2017.
Arymo Er is available in tablet, extended release;oral dosage forms.
Arymo Er can be used as management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
The generics of Arymo Er are possible to be released after 01 July, 2033.
Drugs and Companies using MORPHINE SULFATE ingredient
Market Authorisation Date: 09 January, 2017
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Dosage: TABLET, EXTENDED RELEASE;ORAL
ARYMO ER family patents
